Sarepta shares plummet as lower sales outlook adds to gloom over FDA’s new biologics hire

Already facing headwinds caused by a patient’s death and treatment delays, the biotech now may have to contend with a less friendly FDA.

PTC stock slides on new data for Huntington’s drug

While updated study results confirmed the drug lowers a target protein, the therapy's effect on clinical outcomes was less clear-cut.

A closer look at today's biotech market

Haya banks $65M to scour the ‘dark genome’ for new drugs

The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed by Bristol Myers and Cytokinetics.

Bluebird pleads for deal support; Unity, Mersana lay off staff

Bluebird urged shareholders to back a take-private deal that could close imminently. Elsewhere, Unity Biotechnology began a strategic review and Mersana announced plans to cut more than half its workforce.

Million-dollar gene therapies are providing new hope for people with serious illnesses. But how will we pay for them?

CRISPR isn’t living up to its potential. Two scientists have a plan to fix that

Vertex to expand Casgevy manufacturing in New Hampshire